Emma Louise Robinson

Post doc

Dr Emma Louise Robinson was born in North London, England and grew up in the nearby county of Hertfordshire. After her A-levels, Emma won a place to study Molecular & Cellular Biochemistry at Oxford University, where she was awarded a Nuffield scholarship for Academic Excellence. After graduating from Oxford in 2010, Emma moved to the University of Cambridge where she won a Wellcome Trust PhD studentship in Cardiovascular & Metabolic Disease and started her PhD research under the supervision of Prof. LLewelyn Roderick at The Babraham Institute in Cambridge.

In 2014, LLewelyn and Emma moved to KU Leuven, Belgium to join as Professor in the Laboratory of Experimental Cardiology alongside Prof. Karin Sipido. In Leuven in 2015, Emma was awarded an International scholarship from the KU Leuven Faculty of Medicine in order to complete her PhD research and thesis and obtain her PhD from the University of Cambridge. Throughout her PhD years, Emma was heavily involved in a number of projects, including investigating the roles of non-coding RNAs, histone lysine methylation and DNA methylation in regulation of the transcriptome in cardiac ageing, hypertrophy and disease-associated remodelling.

In 2018, Emma joined the lab of Prof. Stephane Heymans as a post-doctoral scientist, funded by the prestigious CVON Early HFPEF grant from the Dutch Heart Foundation. In Maastricht, Emma’s research focus is on identifying novel biomarkers for early detection of heart failure with preserved ejection fraction (HFpEF) and investigating novel mechanisms in the pathophysiology of this condition, for which common-place clinical biomarkers and neurohumoral-targeting treatments for heart failure are frequently ineffective. In 2018, Emma was awarded a CVON RECONNECT Talent grant to support her research on epigenetic mechanisms underlying pathophysiology of HFpEF.

Department of Cardiology
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: G3.250
T: +31(0)43 388 33 47

  • 2021
    • Badimon, L., Robinson, E. L., Jusic, A., Carpusca, I., DeWindt, L. J., Emanueli, C., Ferdinandy, P., Gu, W., Gyongyosi, M., Hackl, M., Karaduzovic-Hadziabdic, K., Lustrek, M., Martelli, F., Nham, E., Potocnjak, I., Satagopam, V., Schneider, R., Thum, T., & Devaux, Y. (2021). Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129. Cardiovascular Research, 117(8), 1823-1840. https://doi.org/10.1093/cvr/cvab094
    • Meier, S., Henkens, M., Heymans, S., & Robinson, E. L. (2021). Unlocking the Value of White Blood Cells for Heart Failure Diagnosis. Journal of Cardiovascular Translational Research, 14(1), 53-62. https://doi.org/10.1007/s12265-020-10007-6
  • 2020
    • Robinson, E. L., Azodi, M., Heymans, S., & Heggermont, W. (2020). Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions : Where Do we Stand with Chemotherapyinduced Cardiotoxicity?Current Heart Failure Reports, 17(6), 357-364. https://doi.org/10.1007/s11897-020-00489-5
    • Robinson, E. L., Alkass, K., Bergmann, O., Maguire, J. J., Roderick, H. L., & Davenport, A. P. (2020). Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes. Journal of Molecular and Cellular Cardiology, 147, 88-91. https://doi.org/10.1016/j.yjmcc.2020.08.009
    • Verdonschot, J. A. J., Derks, K. W. J., Hazebroek, M. R., Wang, P., Robinson, E. L., Adriaens, M. E., Krapels, I. P. C., van den Wijngaard, A., Brunner, H. G., & Heymans, S. R. B. (2020). Distinct Cardiac Transcriptomic Clustering in Titin and Lamin A/C-Associated Dilated Cardiomyopathy Patients. Circulation, 142(12), 1230-1232. https://doi.org/10.1161/circulationaha.119.045118
    • Henkens, M. T. H. M., Remmelzwaal, S., Robinson, E. L., van Ballegooijen, A. J., Aizpurua, A. B., Verdonschot, J. A. J., Raafs, A. G., Weerts, J., Hazebroek, M. R., Wijk, S. S., Handoko, M. L., den Ruijter, H. M., Lam, C. S. P., de Boer, R. A., Paulus, W. J., van Empel, V. P. M., Vos, R., Brunner-La Rocca, H-P., Beulens, J. W. J., & Heymans, S. R. B. (2020). Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European journal of heart failure, 22(9), 1586-1597. https://doi.org/10.1002/ejhf.1944
    • Jusic, A., Salgado-Somoza, A., Paes, A. B., Stefanizzi, F. M., Martinez-Alarcon, N., Pinet, F., Martelli, F., Devaux, Y., Robinson, E. L., Novella, S., & EU-CardioRNA COST Action (2020). Approaching Sex Differences in Cardiovascular Non-Coding RNA Research. International journal of molecular sciences, 21(14), [4890]. https://doi.org/10.3390/ijms21144890
    • Robinson, E. L., Gomes, C. P. C., Potocnjak, I., Hellemans, J., Betsou, F., de Gonzalo-Calvo, D., Stoll, M., Yilmaz, M. B., Agg, B., Beis, D., Carmo-Fonseca, M., Enguita, F. J., Dogan, S., Tuna, B. G., Schroen, B., Ammerlaan, W., Kuster, G. M., Carpusca, I., Pedrazzini, T., ... EU-CardioRNA COST Action (2020). A Year in the Life of the EU-CardioRNA COST Action: CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease. Non-coding RNA, 6(2), [17]. https://doi.org/10.3390/ncrna6020017
    • Emanueli, C., Badimon, L., Martelli, F., Potočnjak, I., Carpusca, I., Robinson, E. L., & Devaux, Y. (2020). Call to action for the cardiovascular side of COVID-19: A call for cooperative action from the EU-CardioRNA COSTAction. European Heart Journal, 41(19), 1796-1797. https://doi.org/10.1093/eurheartj/ehaa301
    • Verdonschot, J. A. J., Robinson, E. L., James, K. N., Mohamed, M. W., Claes, G. R. F., Casas, K., Vanhoutte, E. K., Hazebroek, M. R., Kringlen, G., Pasierb, M. M., van den Wijngaard, A., Glatz, J. F. C., Heymans, S. R. B., Krapels, I. P. C., Nahas, S., Brunner, H. G., & Szklarczyk, R. (2020). Mutations in PDLIM5 are rare in dilated cardiomyopathy but are emerging as potential disease modifiers. Molecular genetics & genomic medicine, 8(2), [e1049]. https://doi.org/10.1002/mgg3.1049